Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors
January 26 2021 - 9:45AM
Business Wire
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses and companion
delivery systems for the eye, today announced the appointments of
Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K.
Peony Yu, M.D., retired Chief Medical Officer, FibroGen Inc., to
its Board of Directors, effective January 21, 2021.
“The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our
Board of Directors illustrates STAAR’s commitment to excellence,
the surgeon community and growth," said Dr. Gil Kliman, Chairman of
the Nominating and Governance Committee of STAAR Surgical’s Board
of Directors. "Elizabeth is a renowned, highly-respected ophthalmic
surgeon, and thought leader within the Ophthalmology community. For
several years, she has served as a member of the Executive
Committee of the American Society of Cataract and Refractive
Surgery. Peony is an accomplished physician and healthcare
executive who, with more than 25 years of biomedical leadership and
patient care experience, has led key clinical programs and global
product approvals. Elizabeth and Peony collectively bring a wealth
of additional clinical, business and growth perspectives, and we
are delighted to have both doctors join STAAR’s Board.”
“As we pursue our strategic imperative of leading the lens-based
future of refractive vision correction, I couldn’t be more thrilled
to have Elizabeth and Peony join our Board,” said Caren Mason,
President and CEO of STAAR Surgical. “Their significant medical and
industry expertise will provide valuable contributions as we aim to
facilitate visual freedom for patients with our EVO family of
implantable Collamer® lenses, accelerate our company’s growth and
capture refractive market share, globally.”
STAAR also reported today that Mr. John Moore, who has served as
a member of the Board of Directors since 2008, has chosen to retire
from the Board of Directors when his current term expires,
effective at STAAR’s 2021 Annual Shareholders Meeting. Mr.
Silverman, STAAR’s chairman of the Board of Directors, said,
“John’s contributions to STAAR over the past 12 years have been
significant and meaningful. We relied on John’s technical
expertise, and have valued his insights in shaping the company’s
growth and supporting STAAR’s leadership team. The entire Board is
thankful for John’s service to STAAR and wish John and his family
all the best following his retirement.”
The other current members of STAAR’s Board of Directors include
Stephen Farrell, Thomas Frinzi, Gilbert Kliman, M.D., Caren Mason,
and Louis Silverman.
About Elizabeth Yeu,
M.D.
Dr. Elizabeth Yeu, M.D., has been a Partner at Virginia Eye
Consultants since 2014. She also currently serves as Secretary and
a member of the Executive Committee of the American Society of
Cataract and Refractive Surgery (ASCRS). Dr. Yeu is a nationally
recognized ophthalmologist and educator. She has authored hundreds
of articles and is a frequent lecturer in the areas of refractive
cataract surgery, anterior segment reconstruction, ocular surface
disease management and surgical management of astigmatism. Dr. Yeu
was voted to The Ophthalmologist's Power List 2020, Top 100; Power
List 2019, Emerging Leader; Power List 2017, Rising Stars; and 2015
Top 40 Under 40. She was identified as a Clinical Rising Star 2018
by the Ophthalmic Innovations Summit (OIS), was recognized as a
Castle Connelly Top Doc 2016-2019 and received the Castle Connelly
Exceptional Women in Medicine Award in 2017. Dr. Yeu earned her
medical degree through an accelerated and combined
undergraduate/medical school program at the University of Florida
College of Medicine. Dr. Yeu completed her residency at Rush
University Medical Center and fellowship in cornea, anterior
segment and refractive surgery at Baylor College of Medicine.
About K. Peony Yu, M.D.
K. Peony Yu, MD brings more than 25 years of biomedical
leadership, patient care, and medical device development experience
with expertise in clinical and regulatory process, and with
multiple prior successful product approvals for patients in
multiple global regions, including US, Europe, China, Japan, and
others. Dr. Yu served as Chief Medical Officer, FibroGen Inc., a
publicly-traded biopharmaceutical company until December 2020. She
initially joined FibroGen in 2008 as Vice President, Clinical
Development. Prior to joining FibroGen, Dr. Yu served as Vice
President of Clinical Research at Anesiva Inc., following roles of
increasing responsibilities in Clinical Development at ALZA
Corporation, Johnson & Johnson; Pain Therapeutics Inc. (now
Cassava Sciences Inc); and Elan Corporation plc (now Perrigo
Company plc). Earlier in her career, Dr. Yu was Head of the
Department of Physical Medicine & Rehabilitation at the Palo
Alto Medical Foundation. Dr. Yu received a B.S. in Chemical
Engineering from University of California, Davis, and an M.D. from
the UC Davis School of Medicine. She completed her residency
training at Stanford University School of Medicine.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures and markets
implantable lenses for the eye, with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL,” which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian® ICLs have been implanted to date and STAAR
markets these lenses in over 75 countries. To learn more about the
ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210126005807/en/
Investors & Media Brian Moore Vice President,
Investor, Media Relations and Corporate Development (626) 303-7902,
Ext. 3023 bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Apr 2024 to May 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From May 2023 to May 2024